Cargando…
Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up
Duchenne Muscular Dystrophy (DMD) is a X-linked progressive lethal muscle wasting disease for which there is no cure. We present first-in-human study assessing safety and efficacy of novel Dystrophin Expressing Chimeric (DEC) cell therapy created by fusion of patient myoblasts with myoblasts of norm...
Autores principales: | Heydemann, Ahlke, Bieganski, Grzegorz, Wachowiak, Jacek, Czarnota, Jarosław, Niezgoda, Adam, Siemionow, Krzysztof, Ziemiecka, Anna, Sikorska, Maria H., Bozyk, Katarzyna, Tullius, Stefan G., Siemionow, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366026/ https://www.ncbi.nlm.nih.gov/pubmed/37000376 http://dx.doi.org/10.1007/s12015-023-10530-4 |
Ejemplares similares
-
Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration
por: Siemionow, Maria, et al.
Publicado: (2023) -
Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic–Intraosseous Administration
por: Niezgoda, Adam, et al.
Publicado: (2023) -
Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy
por: Siemionow, Maria, et al.
Publicado: (2018) -
Intraosseous transplant of dystrophin expressing chimeric (DEC) cells improves skeletal muscle function in mdx mouse model of Duchenne muscular dystrophy
por: Malik, Mohammad, et al.
Publicado: (2021) -
Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy
por: Siemionow, Maria, et al.
Publicado: (2021)